J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

HealthDay News — Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published online Nov. 27 in Nutrients.

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...

SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...

Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...

Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...

Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...

Maybe your child has been on a specific treatment for atopic dermatitis (also called eczema) for months or even years, but now flare-ups seem to be happening more often and with greater intensity. Or ...